| Unique ID issued by UMIN | UMIN000063698 |
|---|---|
| Receipt number | R000072537 |
| Scientific Title | A study of the effects of intake of food ingredients on peripheral blood flow in healthy adults -Randomized, double-blind, placebo-controlled, parallel-group study- |
| Date of disclosure of the study information | 2026/11/19 |
| Last modified on | 2026/11/18 12:01:21 |
A study of the effects of intake of food ingredients on peripheral blood flow in healthy adults -Randomized, double-blind, placebo-controlled, parallel-group study-
A study of the effects of intake of food ingredients on peripheral blood flow
A study of the effects of intake of food ingredients on peripheral blood flow in healthy adults -Randomized, double-blind, placebo-controlled, parallel-group study-
A study of the effects of intake of food ingredients on peripheral blood flow
| Japan |
None
| Adult |
Others
NO
To evaluate the effects of intake of food ingredients on peripheral blood flow.
Efficacy
Peripheral blood flow
Other circulatory parameters
Skin surface temperature
Related subjective evaluations
Blood biochemical analysis
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
NO
Central registration
2
Treatment
| Food |
Intake of the test food for 6 weeks
Intake of the placebo food for 6 weeks
| 30 | years-old | <= |
| 55 | years-old | > |
Male and Female
(1) Men and women who are aged 30 years or older and under 55 years at the time of obtaining informed consent
(2) Individuals who are judged to be in good health by the principal investigator
(3) Individuals who experience coldness in their hands and feet in daily life
(4) Individuals who experience decreased vigor/vitality or fatigue in daily life
(5) Individuals who are able to visit the study site and undergo examinations on the designated examination dates
(6) Individuals who have received a sufficient explanation of the purpose and details of the study, have the capacity to consent, fully understand the study, voluntarily wish to participate, and are able to provide written informed consent to participate in the study
(7) Individuals who are deemed appropriate to participate in the study by the principal investigator
(1) Individuals who are receiving continuous drug treatment for any disease, or regularly using pharmaceutical or quasi-drug products for purposes other than disease treatment
(2) Individuals who have continuously used pharmaceutical or quasi-drug products for disease treatment within the past month
(3) Individuals who have a history or current diagnosis of diabetes, pulmonary, renal, hepatic, heart, serious gastrointestinal, or other serious disease
(4) Individuals who have symptoms of severe anemia
(5) Individuals who are at risk of allergy to study food ingredients, or who have a history of serious food or drug allergy
(6) Individuals who have a history of reactions to cold water or cold stimuli, such as urticaria, redness, itching, numbness, decreased blood pressure, or difficulty breathing, or who have cold urticaria or allergic reactions to cold stimuli
(7) Individuals who are breastfeeding, pregnant or possibly pregnant, or wish to become pregnant during the study
(8) Individuals who have a history or current diagnosis of drug or alcohol dependence, or who have a psychiatric disorder that may affect study participation
(9) Individuals who habitually consume excessive amounts of alcohol
(10) Individuals who have a smoking habit
(11) Individuals who have habitually engaged, within the past month, in moderate- or higher-intensity physical activity for 150 minutes or more per week, or in muscle-strengthening activities on 2 or more days per week
(12) Individuals whose BMI is less than 18.5 kg/m2 or 25.0 kg/m2 or higher
(13) Individuals who are currently using or have used antihistamines within the past month
(14) Individuals who have experienced or are expected to experience a life event that may have a significant psychological impact during the study period
(15) Individuals who have irregular lifestyles or dietary habits
(16) Individuals who are judged by a physician to have severe cold sensitivity accompanied by Raynaud's phenomenon or similar symptoms
140
| 1st name | Masahiko |
| Middle name | |
| Last name | Morita |
Kirin Holdings Company, Limited
Institute of Health Sciences
251-8555
Shonan Health Innovation Park, 2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan
090-3063-2127
Masahiko_Morita@kirin.co.jp
| 1st name | Masanori |
| Middle name | |
| Last name | Numa |
CPCC Company Limited
Clinical Planning Department
103-0021
4F Daiwa Building, 3-3-10 Nihonbashi-Hongokucho, Chuo-ku, Tokyo 103-0021, Japan
03-6225-9001
cpcc-contact@cpcc.co.jp
Kirin Holdings Company, Limited
Kirin Holdings Company, Limited
Self funding
Research Ethical Review Committee of Kirin Holdings Company, Ltd
Nakano Central Park South, 4-10-2, Nakano, Nakano-ku, Tokyo, Japan
03-6837-4128
02976_Ni@kirin.co.jp
NO
チヨダパラメディカルケアクリニック(東京都)Chiyoda Paramedical Care Clinic
| 2026 | Year | 11 | Month | 19 | Day |
Unpublished
Preinitiation
| 2026 | Year | 11 | Month | 12 | Day |
| 2026 | Year | 11 | Month | 12 | Day |
| 2026 | Year | 12 | Month | 05 | Day |
| 2027 | Year | 12 | Month | 31 | Day |
(Exclusion criteria continued)
(17) Women who have severe menstrual irregularities or severe physical or psychological symptoms associated with premenstrual syndrome (PMS)
(18) Individuals who are unable to avoid exposure to strong direct sunlight, such as through sunbathing, during the study
(19) Individuals who currently or within the past 3 months have habitually consumed supplements, health foods, foods for specified health uses, foods with functional claims, or similar products
(20) Individuals who are currently using or have used within the past 3 months pharmaceutical products claiming beneficial effects on blood flow, blood pressure, or cold sensitivity
(21) Individuals who habitually consume large amounts of specific foods or beverages that may affect study results
(22) Individuals who habitually consume large amounts of caffeine
(23) Individuals who are employed by a company involved in the development, manufacture, or sale of functional foods
(24) Individuals who are currently participating in, scheduled to participate in, or within 4 weeks after completion of another food intake, pharmaceutical use, or cosmetic or pharmaceutical application study
(25) Individuals who are aware that they are infected with hepatitis B or C virus or HIV
(26) Individuals who refuse to disclose their biological sex
(27) Individuals who have donated blood components or 200 mL of whole blood within 1 month before the start of the study
(28) Individuals who have donated 400 mL of whole blood within 3 months before the start of the study
(29) Individuals who are otherwise judged by the principal investigator or sub-investigator to be inappropriate for participation in the study
| 2026 | Year | 11 | Month | 19 | Day |
| 2026 | Year | 11 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072537